|
**Overview**: Neuronal Autoantibodies Panel**Introduction**: The Neuronal Autoantibodies Panel is a diagnostic tool designed to screen for paraneoplastic syndromes using serum samples. In India, paraneoplastic neurological syndromes (PNS) are underrecognized (~few hundred cases/year reported), associated with anti-Hu, anti-Ri, anti-Yo, anti-CV2, anti-PNMA2, anti-amphiphysin in small cell lung cancer, breast cancer, or ovarian tumors, causing subacute encephalomyelitis, cerebellar ataxia, or neuropathy. High morbidity from under-testing in rural/low-SES patients with subacute neurological symptoms and occult malignancy, limited autoantibody labs, delayed tumor search and immunosuppression leading to irreversible deficits or death. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs immunoassay for 6 neuronal autoantibodies over 1-2 days with high specificity, valuable for paraneoplastic diagnosis. This diagnostic falls under autoimmune screening and targets patients with subacute neurological syndromes and cancer risk, addressing accurate detection to guide tumor screening and immunotherapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise antibody identification and improving PNS outcomes. Its serum-based approach ensures reliable autoantibody detection.**Other Names**: Neuronal Ab Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Paraneoplastic antibody panel standard; in India, used in neuro-oncology.**Purpose**: The test assesses 6 parameters including anti-Hu to guide PNS screening, detect paraneoplastic antibodies, inform tumor search.**Test Parameters**: 1. Anti-Hu, 2. Anti-Ri, 3. Anti-Yo, 4. Anti-CV2, 5. Anti-PNMA2, 6. Anti-Amphiphysin.**Pretest Condition**: No fasting required; patients should have subacute neurological symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on neurological symptoms, cancer history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected PNS including progression, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive paraneoplastic antibody indicates underlying malignancy, necessitating specialist input.**Specialist Consultation**: Neurologists or neuro-oncologists should be consulted for management.**Additional Supporting Tests**: CSF analysis, PET-CT for tumor search.**Test Limitations**: Not all PNS antibody-positive; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Paraneoplastic Studies India 2023. |
